Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Restenosis drug discovery--a formidable task.

C Q Meng1

  • 1AtheroGenics Inc, 8995 Westside Parkway, Alpharetta, GA 30004, USA. cmeng@atherogenics.com

Current Opinion in Investigational Drugs (London, England : 2000)
|November 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ezetimibe (Schering-Plough).

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Nitrobenzene compounds inhibit expression of VCAM-1.

Bioorganic & medicinal chemistry letters·2001
Same author

5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists.

Bioorganic & medicinal chemistry letters·2000
Same author

5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.

Bioorganic & medicinal chemistry letters·2000
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Restenosis after angioplasty involves neointima formation and vascular remodeling. Future treatments must target both processes, as current drugs focusing only on neointima formation have largely failed.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Pharmacology

Background:

  • Restenosis, the re-narrowing of arteries after angioplasty, is a significant clinical challenge.
  • Neointima formation and vascular remodeling are key contributors to restenosis development.
  • Stenting improves outcomes but restenosis rates remain high.

Purpose of the Study:

  • To review the pathophysiology of restenosis after angioplasty.
  • To evaluate the effectiveness of current therapeutic strategies.
  • To propose future directions for drug development targeting restenosis.

Main Methods:

  • Literature review of studies on restenosis mechanisms and treatments.
  • Analysis of clinical trial data for drugs targeting neointima formation and remodeling.

Related Experiment Videos

  • Evaluation of antioxidant therapies in the context of restenosis.

    • Main Results:

    • Neointima formation and vascular remodeling are interrelated factors in restenosis.
    • Many drugs targeting neointima formation have failed to prevent restenosis effectively.
    • Stenting mitigates unfavorable remodeling but does not eliminate restenosis.
    • Antioxidants like probucol show promise for addressing both neointima formation and remodeling.

    Conclusions:

    • Effective restenosis prevention requires targeting both neointima formation and vascular remodeling.
    • Future drug design should incorporate strategies to inhibit both processes.
    • Antioxidant therapies warrant further investigation for restenosis prevention.